Tramadol for Dogs Dosage Calculator

Tramadol is an atypical centrally acting analgesic with two mechanisms working at once. The parent molecule is a weak serotonin and norepinephrine reuptake inhibitor, strengthening descending inhibitory pain pathways, while its metabolite O-desmethyltramadol, known as M1, is a mu-opioid agonist with roughly two hundred times the receptor affinity of the parent compound. Species differ sharply in how much M1 they generate. Dogs produce comparatively little and clear it fast, with plasma half-lives for both tramadol and M1 in dogs generally reported in the range of one to three hours, which is why canine dosing is 2 to 5 mg/kg every 8 to 12 hours rather than the twice-daily schedules used in people. Practical dosing is constrained by tablet geometry, since the available supply is human 50 mg and 100 mg tablets. A 20 kg dog at about 3.5 mg/kg lands on one and a half 50 mg tablets, and doses are conventionally rounded to the nearest half tablet. Total daily exposure is usually kept near or below about 15 mg/kg. The safety concerns are specific rather than general. Tramadol lowers the seizure threshold and is avoided in dogs with a seizure history; combined with SSRIs, tricyclics, trazodone, or the monoamine oxidase inhibitor selegiline it can precipitate serotonin syndrome; and after prolonged administration it is tapered rather than stopped abruptly. Sedation, constipation, panting, and reduced appetite are the routine complaints, and the bitter taste makes pilling difficult in some dogs.

Tramadol was synthesised in 1962 by chemists at Grunenthal, the West German pharmaceutical company, and was marketed in Germany as Tramal from 1977. It reached the United States in 1995 as Ultram, promoted at the time as an opioid-sparing analgesic that was not a controlled substance. That status did not survive scrutiny of abuse and dependence reports, and the US Drug Enforcement Administration placed tramadol in Schedule IV in 2014. Veterinary use was always extra-label, expanding through the late 1990s and 2000s as multimodal pain protocols replaced single-drug regimens. Pharmacokinetic work in dogs, notably by Butch KuKanich and Mark Papich in the mid-2000s, showed that dogs generate far less M1 than humans do, undermining the assumption that canine tramadol works mainly through the opioid receptor. Clinical trials followed the pharmacology. A 2018 randomised study by Steven Budsberg and colleagues in the Journal of the American Veterinary Medical Association found tramadol no better than placebo for osteoarthritis of the canine elbow. Prescribing has since shifted toward NSAIDs, gabapentin, amantadine and anti-nerve-growth-factor monoclonal antibodies, with tramadol retained as an adjunct where those options are contraindicated.